Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Mehr anzeigen
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.41 | -18.0076628352 | 7.83 | 7.9747 | 6.3601 | 7324131 | 7.41837293 | CS |
| 4 | -1.48 | -18.7341772152 | 7.9 | 8.15 | 6.3601 | 7152826 | 7.45377576 | CS |
| 12 | -3.84 | -37.4269005848 | 10.26 | 12.505 | 6.3601 | 7082768 | 8.97681613 | CS |
| 26 | -1.15 | -15.1915455746 | 7.57 | 12.505 | 6.3601 | 6522918 | 9.32300903 | CS |
| 52 | -3.53 | -35.4773869347 | 9.95 | 18.33 | 6.3601 | 7124070 | 10.65621316 | CS |
| 156 | -9.83 | -60.4923076923 | 16.25 | 18.73 | 3.21 | 5441614 | 9.14328105 | CS |
| 260 | -21.47 | -76.980996773 | 27.89 | 54.2081 | 3.21 | 4021106 | 12.85016454 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
